title: Ending AIDS as a public health threat by 2030: Scientific Developments from the 2016 INTEREST Conference in Yaoundé, Cameroon.
abstract: The underpinning theme of the 2016 INTEREST Conference held in Yaoundé, Cameroon, 3-6 May 2016 was ending AIDS as a public health threat by 2030. Focused primarily on HIV treatment, pathogenesis and prevention research in resource-limited settings, the conference attracted 369 active delegates from 34 countries, of which 22 were in Africa. Presentations on treatment optimization, acquired drug resistance, care of children and adolescents, laboratory monitoring and diagnostics, implementation challenges, HIV prevention, key populations, vaccine and cure, hepatitis C, mHealth, financing the HIV response and emerging pathogens, were accompanied by oral, mini-oral and poster presentations. Spirited plenary debates on the UNAIDS 90-90-90 treatment cascade goal and on antiretroviral pre-exposure prophylaxis took place. Joep Lange career guidance sessions and grantspersonship sessions attracted early career researchers. At the closing ceremony, the Yaoundé Declaration called on African governments; UNAIDS; development, bilateral, and multilateral partners; and civil society to adopt urgent and sustained approaches to end HIV by 2030.
authors.affiliation: Amsterdam Institute for Global Health and Development (AIGHD), Department of Global Health, University of Amsterdam, Amsterdam, the Netherlands.|London School of Hygiene and Tropical Medicine, London, UK.
authors.forename: Catherine A
authors.initials: CA
authors.lastname: Hankins
authors.affiliation: Ministry of Health, Yaoundé, Cameroon.
authors.forename: Sinata
authors.initials: S
authors.lastname: Koulla-Shiro
authors.affiliation: National Institutes of Health, Fogarty International Center, Bethesda, MD, USA.
authors.forename: Peter
authors.initials: P
authors.lastname: Kilmarx
authors.affiliation: Duke University Medical Center, Department of Surgery, Durham, NC, USA.
authors.forename: Guido
authors.initials: G
authors.lastname: Ferrari
authors.affiliation: Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
authors.forename: Mauro
authors.initials: M
authors.lastname: Schechter
authors.affiliation: Laboratoire de Bacteriologie-Virologie CHU Le Dantec, Dakar University, Dakar, Senegal.
authors.forename: Coumba Touré
authors.initials: CT
authors.lastname: Kane
authors.affiliation: Wits Reproductive Health and HIV Institute, University of the Witwatersrand, Johannesburg, South Africa.
authors.forename: François
authors.initials: F
authors.lastname: Venter
authors.affiliation: Erasmus Medical Center, Department of Viroscience, Rotterdam, the Netherlands.
authors.forename: Charles Ab
authors.initials: CA
authors.lastname: Boucher
authors.affiliation: National Agency for AIDS Research (ANRS), Paris, France.
authors.forename: Anna-Laura
authors.initials: AL
authors.lastname: Ross
authors.affiliation: CUNY School of Public Health and Public Policy, New York, NY, USA.
authors.forename: Debrework
authors.initials: D
authors.lastname: Zewdie
authors.affiliation: CHU de Treichville, University of Abidjan, Abidjan, Ivory Coast.
authors.forename: Serge Paul
authors.initials: SP
authors.lastname: Eholié
authors.affiliation: Makarere University College of Health Sciences in Kampala, Kampala, Uganda.
authors.forename: Elly
authors.initials: E
authors.lastname: Katabira
mesh_terms: D016915:AIDS Vaccines / Q000096:biosynthesis / Q000627:therapeutic use*; D000163:Acquired Immunodeficiency Syndrome / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D000293:Adolescent; D000328:Adult; D019380:Anti-HIV Agents / Q000138:chemical synthesis / Q000627:therapeutic use*; D002163:Cameroon; D002648:Child; D060740:Disease Eradication / Q000331:legislation & jurisprudence; D005544:Forecasting; D006801:Humans; D007391:International Cooperation; D065129:Pre-Exposure Prophylaxis; D011634:Public Health / Q000191:economics / Q000639:trends*
chemical_list: D016915:AIDS Vaccines; D019380:Anti-HIV Agents